Pharma/fine chemicals roundup—24 February 2015
6:10 AM MST | February 24, 2015 | By DEEPTI RAMESH
Granules OmniChem JV opens API plant in India
Granules India (Hyderabad), a producer of active pharmaceutical ingredients (APIs), intermediates, and formulations, says that its Granules OmniChem joint venture has opened its previously announced new manufacturing facility for APIs and pharma intermediates at Visakhapatnam, India. Granules India formed Granules OmniChem — a 50-50 jv with pharmaceutical fine chemicals firm Ajinomoto OmniChem (Louvain-la-Neuve, Belgium), a wholly owned subsidiary of Ajinomoto (Tokyo) — in 2011. The project had originally been expected to become operational in 2013, but the start of production at the facility was pushed back primarily due to a delay in receiving government clearance; after receiving clearance from the government, the jv faced minimal delays during the actual construction, Granules India told CW last year. The jv will focus on sales to the regulated markets, and will have significant revenues only after the facility gets US FDA approval in 2017, Granules India told CW.
Sanofi names head of Bayer HealthCare as new CEO, Bayer announces successor
Health-care major Sanofi (Paris) says that its board has unanimously appointed Olivier Brandicourt—currently head of Bayer HealthCare—as the new CEO of Sanofi. Brandicourt’s tenure as CEO of Sanofi will commence on 2 April. Brandicourt will replace Christopher Viehbacher, whom the Sanofi board fired in October 2014.Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as chairman of the board of management of Bayer HealthCare and member of the executive council of Bayer since November 2013. Previously, Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups, such as Parke-Davis/Warner-Lambert and Pfizer. Brandicourt served as a member of Pfizer's global executive leadership team from 2010–13, Sanofi says.
Separately, Bayer confirmed that Brandicourt will be leaving the company on 31 March and that Werner Baumann, member of the board of management of Bayer, will take over the function of chairman at Bayer HealthCare, effective 2 April. Baumann will remain a member of Bayer's board and executive council. He will also retain responsibility for strategy and portfolio management as well as for Europe.
Novasep selected to manufacture Celladon’s Mydicar API
Novasep (Pompey, France), a supplier of services and technologies to the life sciences industry, says that it has entered into an agreement with Celladon (San Diego), a clinical-stage biotechnology company, under which Novasep will supply the drug substance or the active ingredient for Celladon’s Mydicar. Mydicar is a genetically-targeted enzyme replacement therapy for advanced heart failure. The deal covers scale-up and pre-validation studies, and as part of the agreement, Novasep will enhance its Seneffe, Belgium bioproduction plant. In addition, Novasep and Celladon have agreed to negotiate terms for a commercial supply agreement that will be valid until the end of 2018. “We are leveraging over ten years’ experience in developing and manufacturing viruses and viral vector products to enable Celladon to meet its goal of bringing Mydicar to the market as soon as possible,” says Alain Lamproye, president of Novasep’s biopharma unit.
Teijin and Nakashima form JV for medical devices
Teijin announced that it will acquire, through a third-party allotment, new shares of Nakashima Medical (Okayama, Japan), a wholly owned subsidiary of Nakashima Holdings (Okayama) that specializes in joint prostheses, in order to establish a 50-50 joint venture called Teijin Nakashima Medical. Nakashima Medical will change its name to Teijin Nakashima Medical and operate as a jv beginning 1 April. The jv will develop a global medical devices business by integrating Nakashima’s core competencies in metalworking and joint prostheses with Teijin’s expertise in materials technology, primarily polymeric chemistry, and health-care-related development and sales capabilities. The headquarters, production plant, and R&D center of Teijin Nakashima Medical will be located at Okayama. The jv will employ about 186 people and will mainly be involved in developing, manufacturing, and selling medical devices, including joint prostheses and trauma implants.
Beyond IHS Chemical Week:
Rebooting HAL part of Indian plans to boost API capacity and cut reliance on China
The Indian Government wants to build API production capacity and revive state run manufacturer Hindustan Antibiotics to cut reliance on Chinese imports. The plan was outlined at an event hosted by Assocham in Delhi last week. Department of Pharmaceuticals secretary VK Subburaj told delegates "more than 80% of bulk drugs [APIs] are coming from one source — China. So we want to reduce this dependency, and we need to create capacities.”
Connect with IHS Chemical Week
Our related sites